title: Influence of treatment strategy on serum adiponectin, resistin and angiogenin concentrations in patients with stable multivessel coronary artery disease after one-year follow-up.
abstract: BACKGROUND
  Adiponectin and resistin, as well as the novel angiogenetic factor angiogenin, may be associated with inflammation and atherosclerosis. However, the available data are limited regarding adipocytokines and angiogenesis factors long-term serum concentration changes in patients with coronary artery disease (CAD).
  
  
  OBJECTIVE
  To evaluate the treatment strategy-dependent changes in serum concentrations of adiponectin, resistin and angiogenin in patients with stable multivessel CAD (MCAD) and their association with cardiovascular events.
  
  
  METHODS
  The study group comprised 107 MCAD patients (80 males, mean age 63±8 years); 55 (51%) patients were treated surgically (coronary artery bypass grafting-CABG), while the other 52 (49%) were treated medically. Adiponectin, resistin and angiogenin plasma levels were measured on admission and after one-year follow-up. Major adverse cardiac events (MACE) were defined as cardiac death, non-fatal myocardial infarction, stroke or hospitalisation for angina or heart failure over the 12 month period.
  
  
  RESULTS
  During one-year follow-up, nine (8%) patients died, all from cardiovascular causes, and 34 (32%) patients experienced MACE. The CABG group revealed significant decrease in angiogenin (p<0.0001) and adiponectin (p=0.03) serum levels. In the medically treated group, we noted a significant reduction in the adiponectin serum concentration (p=0.003), with no change in resistin and angiogenin serum levels.
  
  
  CONCLUSIONS
  In stable patients with MCAD, the choice of treatment strategy (optimal medical therapy or surgery) influences cytokines profile and modifies serum concentration of angiogenin and adiponectin during 12 months of follow-up. Assessing the dynamic concentration changes of these novel biomarkers may be useful for clinical practice.
authors.affiliation: 2nd Department of Cardiology, Medical University of Lodz, Biegański Hospital, Łódź, Poland. rkrecki@ptkardio.pl
authors.forename: Radosław
authors.initials: R
authors.lastname: Kręcki
authors.forename: Maria
authors.initials: M
authors.lastname: Krzemińska-Pakuła
authors.forename: Jan Zbigniew
authors.initials: JZ
authors.lastname: Peruga
authors.forename: Piotr
authors.initials: P
authors.lastname: Szcześniak
authors.forename: Piotr
authors.initials: P
authors.lastname: Lipiec
authors.forename: Daria
authors.initials: D
authors.lastname: Orszulak-Michalak
authors.forename: Jarosław Damian
authors.initials: JD
authors.lastname: Kasprzak
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood* / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D052243:Resistin / Q000097:blood*; D012259:Ribonuclease, Pancreatic / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D052243:Resistin; C046366:angiogenin; D012259:Ribonuclease, Pancreatic